Related Experiment Video
Updated: Jun 7, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
miR-29 is a major regulator of genes associated with pulmonary fibrosis
Leah Cushing1, Ping Ping Kuang, Jun Qian
1Pulmonary Center, Department of Medicine, Boston University School of Medicine, Massachusetts, USA.
Abstract:
MicroRNAs (miRNA) are small regulatory RNAs that control gene expression by translational suppression and destabilization of target mRNAs. There is increasing evidence that miRNAs regulate genes associated with fibrosis in organs, such as the heart, kidney, liver, and the lung. In a large-scale screening for miRNAs potentially involved in bleomycin-induced fibrosis, we found expression of miR-29 family members significantly reduced in fibrotic lungs. Analysis of normal lungs showed the presence of miR-29 in subsets of interstitial cells of the alveolar wall, pleura, and at the entrance of the alveolar duct, known sites of pulmonary fibrosis. miR-29 levels inversely correlated with the expression levels of profibrotic target genes and the severity of the fibrosis. To study the impact of miR-29 down-regulation in the lung interstitium, we characterized gene expression profiles of human fetal lung fibroblast IMR-90 cells in which endogenous miR-29 was knocked down. This confirmed the derepression of reported miR-29 targets, including several collagens, but also revealed up-regulation of a large number of previously unrecognized extracellular matrix-associated and remodeling genes. Moreover, we found that miR-29 is suppressed by transforming growth factor (TGF)-β1 in these cells, and that many fibrosis-associated genes up-regulated by TGF-β1 are derepressed by miR-29 knockdown. Interestingly, a comparison of TGF-β1 and miR-29 targets revealed that miR-29 controls an additional subset of fibrosis-related genes, including laminins and integrins, independent of TGF-β1. Together, these strongly suggest a role of miR-29 in the pathogenesis of pulmonary fibrosis. miR-29 may be a potential new therapeutic target for this disease.
Insights
MicroRNAs (miRNAs) are key regulators of gene expression. Reduced miR-29 levels in fibrotic lungs suggest its potential role in pulmonary fibrosis and as a therapeutic target.
Area of Science:
- Molecular Biology
- Genetics
- Pulmonary Medicine
Background:
- MicroRNAs (miRNAs) are small regulatory RNAs impacting gene expression.
- Evidence suggests miRNAs are involved in fibrotic diseases across multiple organs.
- Pulmonary fibrosis is a significant health concern with limited therapeutic options.
Purpose of the Study:
- To investigate the role of microRNAs in pulmonary fibrosis.
- To identify specific miRNA dysregulation in fibrotic lung tissue.
- To explore the therapeutic potential of miRNAs in treating lung fibrosis.
Main Methods:
- Large-scale screening of miRNAs in bleomycin-induced fibrosis models.
- Analysis of miR-29 expression in normal and fibrotic human lung tissue.
- Gene expression profiling of human fetal lung fibroblasts with miR-29 knockdown.
- Investigating the interaction between miR-29 and transforming growth factor (TGF)-β1 signaling.
Main Results:
- miR-29 family members were significantly downregulated in fibrotic lungs.
- miR-29 levels inversely correlated with profibrotic gene expression and fibrosis severity.
- miR-29 knockdown led to derepression of known and novel extracellular matrix genes.
- miR-29 is suppressed by TGF-β1, and it regulates fibrosis-associated genes independently of TGF-β1.
Conclusions:
- The miR-29 family plays a crucial role in the pathogenesis of pulmonary fibrosis.
- Dysregulation of miR-29 contributes to the development of lung fibrosis.
- miR-29 represents a promising therapeutic target for pulmonary fibrosis.
Related Concept Videos
Master Transcription Regulators
MicroRNAs
MicroRNAs
